{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:37:51Z","timestamp":1775083071044,"version":"3.50.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    A 72-year-old man presented with right-sided rigidity and bradykinesia, but the history and neurological examination were not entirely compatible with degenerative parkinsonism. Initial MRI showed T2\/FLAIR hyperintensity within the splenium, attributed to small vessel disease. Subsequent\n                    <jats:sup>18<\/jats:sup>\n                    F-FDOPA brain PET\/MRI ruled out degenerative parkinsonism, but revealed avid tracer uptake (SUVmax 4.46) in the splenium corresponding to signal abnormality on structural imaging. This unexpected finding prompted contrast-enhanced MRI brain, which identified a peripherally enhancing splenium lesion concerning for neoplasm. Stereotactic biopsy confirmed GFAP-positive, diffuse high-grade glioblastoma, IDH-wildtype, WHO Grade 4, highlighting the role of FDOPA PET in the assessment of primary brain tumors.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006337","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:00:08Z","timestamp":1768842008000},"page":"434-435","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Parkinsonism: 18F-FDOPA Brain PET\/MRI for Detection of High-grade Glioma"],"prefix":"10.1097","volume":"51","author":[{"given":"Michelle","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiology, Neuroradiology Division, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Lenox Hill Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Niethammer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Manhasset, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2577-9738","authenticated-orcid":false,"given":"Ana M.","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Neuroradiology Division, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Lenox Hill Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/ph17091215","article-title":"Complex diagnostic challenges in glioblastoma: the role of 18F-FDOPA PET imaging","volume":"17","author":"Sipos","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur J Nucl Meda Mol Imaging"},{"key":"R3-20260401","first-page":"656","article-title":"Dynamic 18F-FDOPA-PET\/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology","volume":"7","author":"Ponisio","year":"2020","journal-title":"Neurooncol Pract"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"Albert","year":"2016","journal-title":"Neuro Oncol"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1007\/s00259-024-06720-y","article-title":"The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions","volume":"51","author":"Zinsz","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-018-2877-6","article-title":"18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-na\u00efve gliomas: a cross-sectional study","volume":"139","author":"Patel","year":"2018","journal-title":"J Neurooncol"},{"key":"R7-20260401","first-page":"5117","article-title":"The role of PET [18F]FDOPA in evaluating low-grade glioma","volume":"35","author":"Villani","year":"2015","journal-title":"Anticancer Res"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"e16093","DOI":"10.1111\/ene.16093","article-title":"Exploring the mechanism of 18F-fluorodopa uptake in recurrent high-grade gliomas: a comprehensive histomolecular-positron emission tomography analysis","volume":"31","author":"Cobes","year":"2024","journal-title":"Eur J Neurol"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1007\/s00330-013-2838-6","article-title":"Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma","volume":"23","author":"Karunanithi","year":"2013","journal-title":"Eur Radiol"},{"key":"R10-20260401","first-page":"904","article-title":"18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy","volume":"47","author":"Chen","year":"2006","journal-title":"J Nucl Med"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40644-020-00348-5","article-title":"Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature","volume":"20","author":"Somme","year":"2020","journal-title":"Cancer Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:57Z","timestamp":1775077257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006337","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"2025-10-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}